Wells Fargo & Company Lexaria Bioscience Corp. Transaction History

Wells Fargo & Company

$407 Billion
Q2 2024

A detailed history of Wells Fargo & Company transactions in Lexaria Bioscience Corp. stock. As of the latest transaction made, Wells Fargo & Company holds 3,300 shares of LEXX stock, worth $9,966. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,300

Previous 1,073 207.55%

Holding current value

$9,966

Previous $3,000 200.0%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$1.99 - $4.0 $4,431 - $8,908	2,227 Added 207.55%	3,300 $9,000
Q1 2024 May 10, 2024	BUY	$1.29 - $6.25 $14 - $68	11 Added 1.04%	1,073 $3,000
Q4 2023 Feb 09, 2024	SELL	$0.92 - $1.69 $22 - $40	-24 Reduced 2.21%	1,062 $1,000
Q3 2023 Nov 13, 2023	BUY	$0.72 - $1.11 $10 - $16	15 Added 1.4%	1,086 $1,000
Q2 2023 Aug 15, 2023	BUY	$0.69 - $2.69 $1 - $5	2 Added 0.19%	1,071 $0
Q1 2023 May 12, 2023	BUY	$2.47 - $3.47 $83 - $117	34 Added 3.29%	1,069 $2,000
Q4 2022 Feb 13, 2023	BUY	$1.95 - $2.98 $1 - $2	1 Added 0.1%	1,035 $2,000
Q3 2022 Nov 14, 2022	BUY	$0.74 - $3.28 $1 - $6	2 Added 0.19%	1,034 $2,000
Q2 2022 Aug 12, 2022	BUY	$1.88 - $4.06 $3 - $8	2 Added 0.19%	1,032 $3,000
Q1 2022 May 16, 2022	BUY	$2.78 - $4.7 $13 - $23	5 Added 0.49%	1,030 $3,000
Q4 2021 Feb 14, 2022	BUY	$3.87 - $6.9 $3,870 - $6,900	1,000 Added 4000.0%	1,025 $4,000
Q3 2021 Nov 15, 2021	SELL	$5.39 - $8.44 $21 - $33	-4 Reduced 13.79%	25 $0
Q1 2021 May 13, 2021	BUY	$4.26 - $8.38 $123 - $243	29 New	29 $0

Others Institutions Holding LEXX

# of Institutions

Shares Held

2.06M

Call Options Held

Put Options Held

View Full List

About Lexaria Bioscience Corp.

Ticker LEXX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 5,951,000
Market Cap $18M
Description
Lexaria Bioscience Corp. operates as a biotechnology company. Its patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients enter the bloodstream by promoting effective oral delivery. The company's DehydraTECH has demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x ...

More about LEXX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account

Wells Fargo & Company Lexaria Bioscience Corp. Transaction History